Deerfield, Ill., March 12, 2021 – Lundbeck US, an affiliate of the global biopharmaceutical company H. Lundbeck A/S with U.S. headquarters in suburban Chicago, announced today it has been named a 2021 Best Workplace in Health Care & Biopharma by Fortune and Great Place to Work®. The prestigious recognition comes directly from employee feedback and ranks companies based on employees’ workplace experience.
As the only global biopharmaceutical company solely focused on the brain, the urgent nature of Lundbeck’s work came into sharp focus over the past year. Economic uncertainty, social isolation and increased stress led to a dramatic rise in new mental health challenges. In addition, research shows some people with existing mental illness are at risk for more severe COVID-19 outcomes, and the long-term neurological effects of the virus highlight the vital need for increased research into central nervous system disorders such as chronic pain and migraine.
“As we continue to confront pandemic-related challenges in 2021, we know we can’t meet the complex needs of our patient communities if we ourselves feel depleted,” says Peter Anastasiou, executive vice president and head of Lundbeck North America. “Supporting our colleagues’ emotional health and offering flexibility have been our guiding principles throughout this time. This national recognition reinforces that employees appreciate our efforts.”
The award follows the recent announcement of a refined global strategy to establish Lundbeck as #1 in brain health by 2030. Through a premier neuroscience pipeline filled with assets that will make a transformative difference in patients’ lives, a focused commercial footprint serving niche and rare neurology and niche psychiatry, ambitious sustainability goals, and a heightened focus on leveraging diversity within the organization, Lundbeck aims to serve patients, care partners, families and communities who need new medicines to help them conquer brain diseases.
“We’re at the leading edge of brain disease research, advancing innovative biologics-based approaches to some of the world’s most challenging neurological diseases,” says Mark Fromhold, vice president, process development at Lundbeck Seattle BioPharmaceuticals. “Contributing to an ambitious, patient-first global R&D strategy is exciting and aligns with the Lundbeck global strategy to be #1 brain health.”
“Having the autonomy to maximize the passion of our US-based research team, but also collaborate with our global R&D team on an ambitious patient-centric agenda, makes Lundbeck unique,” says Gary O’Neill, La Jolla Research Center site head. “Together, we are grounded in our purpose to restore brain health, so every person can be their best. And that makes Lundbeck a great place to work.”
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Our approximately 6,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy.
In the United States, Lundbeck employs more than 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities.
For additional information, we encourage you to visit us at www.lundbeckus.com, subscribe to our newsletter at Newsroom.LundbeckUS.com, and connect with us on LinkedIn at @LundbeckUS and Twitter at @LundbeckUS
Corporate Communications Specialist